Company Information
- Type:
- Company
- Country:
- France
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Privately Held
- Global Compact Status:
- Active
- Participant Since
- 05 July 2013 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 26-Jul-2024 | 2024 Communication on Progress | Submitted |
| 30-Jun-2022 | 2022 Communication on Progress | Submitted |
| 18-May-2021 | Rapport RSE 2020 | Active |
| 26-Jan-2021 | Grace Letter | Not applicable |
| 10-Sep-2019 | Reporting Cycle Adjustment | Not applicable |
| 02-Oct-2018 | Communication on Progress | Active |
| 26-Jun-2018 | Grace Letter | Not applicable |
| 30-Jun-2017 | Communication on Progress | Active |
| 01-Jul-2016 | Communication on Progress | Active |
| 01-Jul-2015 | Communication on Progress 2015 | Active |
| 01-Jul-2014 | COP ARKOPHARMA 2014 | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.